Main menu

SAN FRANCISCO, Jan 8 – Investors are expected to take a “back to basics” approach to genomics during 2001 as they seek companies that are generating revenues from fully developed technologies, Rob Olan, a life science technology analyst at JP Morgan H&Q, said Monday.

“In general, the atmosphere is going to be less euphoric,” Olan told GenomeWeb at the start of the JP Morgan H&Q healthcare conference. “Companies that are more established will do better.”